Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

NCT01866748 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions

DRUG: semaglutide
DRUG: semaglutide
DRUG: placebo
DRUG: placebo

Sponsor

Novo Nordisk A/S